

Market Announcement

16 December 2024

Percheron Therapeutics Limited (ASX: PER) – Trading Halt

Description

The securities of Percheron Therapeutics Limited ('PER') will be placed in trading halt at the request of PER, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 18 December 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

16 December 2024

Ms Melissa Kostopoulos
Adviser, Listings Compliance
ASX Compliance Pty Ltd
Level 4, North Tower,
Rialto Building
525 Collins Street
Melbourne VIC 3000

Via email: tradinghaltsmelbourne@asx.com.au

Dear Melissa,

Percheron Therapeutics Limited – Trading Halt Request

In accordance with ASX Listing Rule 17.1, Percheron Therapeutics Limited (ASX:PER) (the **Company**) requests an immediate trading halt in respect of the Company's securities prior to the commencement of trading on Monday, 16 December 2024, pending an announcement in relation to the initial top line data for the Company's phase IIb clinical trial of avicursen (ATL1102) in Duchenne muscular dystrophy.

In accordance with ASX Listing Rule 17.1, the Company provides the following information:

- a) the Company is seeking the trading halt pending an announcement in relation to the initial top line data for the Company's phase IIb clinical trial of avicursen (ATL1102) in Duchenne muscular dystrophy;
- b) the Company requests that the trading halt last until the earlier of the Company releasing an announcement in relation to the initial top line data for its phase IIb clinical trial of avicursen (ATL1102) in Duchenne muscular dystrophy and the commencement of trading on Wednesday, 18 December 2024;
- c) the Company anticipates that the trading halt will cease on it making the announcement in relation to the initial top line data for its phase IIb clinical trial of avicursen (ATL1102) in Duchenne muscular dystrophy;
- d) the Company is not aware of any reason why the trading halt should not be granted; and
- e) the Company is not aware of any further information which needs to be disclosed to the market at the time of seeking the trading halt.

Please do not hesitate to contact me if you require any further information.

Your sincerely,

Deborah Ambrosini
Company Secretary
Percheron Therapeutics Limited